E18B Stock Overview
ETF Series Solutions - Range Cancer Therapeutics ETF is an exchange traded fund launched by ETF Series Solutions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ETF Series Solutions - Range Cancer Therapeutics ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.82 |
| 52 Week High | US$13.72 |
| 52 Week Low | US$8.45 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -5.77% |
| 1 Year Change | -35.71% |
| 3 Year Change | -69.12% |
| 5 Year Change | -52.88% |
| Change since IPO | -67.81% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| E18B | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -1.3% |
| 1Y | -35.7% | 20.1% | 4.1% |
Return vs Industry: E18B underperformed the German Capital Markets industry which returned 8.4% over the past year.
Return vs Market: E18B underperformed the German Market which returned -0.9% over the past year.
Price Volatility
| E18B volatility | |
|---|---|
| E18B Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E18B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E18B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | https://loncarfunds.com/cncr |
ETF Series Solutions - Range Cancer Therapeutics ETF is an exchange traded fund launched by ETF Series Solutions. The fund is managed by Exchange Traded Concepts, LLC. It invests in public equity markets of the United States.
ETF Series Solutions - Range Cancer Therapeutics ETF Fundamentals Summary
| E18B fundamental statistics | |
|---|---|
| Market cap | €14.52m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs E18B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E18B income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did E18B perform over the long term?
See historical performance and comparison